Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC

Next Previous
Trial Profile

A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrilatazar (Primary) ; Carboplatin; Paclitaxel
  • Indications Carcinoma; Endometrial cancer; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Endolung
  • Sponsors Ability Pharmaceuticals

Most Recent Events

  • 01 Mar 2025 Results of phase II study (n=40) assessing efficacy and safety of ibrilatazar combined with chemotherapy in sq-NSCLC patients published in the Lung Cancer.
  • 22 Jul 2024 Results assessing safety and efficacy of Ibrilatazar (ABTL0812) with CP in patients with advanced/recurrent EC and non-irradiable stage III and IV squamous non-small cell lung cancer published in the BMC Cancer
  • 06 Jun 2023 Results(n=40) assessing the safety of ABTL0812 in combination with paclitaxel and carboplatin in first-line patients with advanced squamous non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top